SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Aadi Bioscience, Inc. (AADI) .
Criteria proven by this page:
- VALUE (10/100, Fail) — analyst consensus target implies downside from the current price ($1.63, 20.5%).
- Analyst consensus target $1.63 (-20.5% downside) — analysts see meaningful downside risk at the current price level.
Overall SharesGrow Score: 28/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
10/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — AADI
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio177.56
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.03
Book Value / Share$0.00
Revenue / Share$0.01
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$1.63 (-20.5%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-9.42 |
$0.00 |
$-16.98M |
- |
| 2017 |
$-14.81 |
$0.00 |
$-21.4M |
- |
| 2018 |
$-4.60 |
$20.16M |
$-10.4M |
-51.6% |
| 2019 |
$-8.60 |
$749K |
$-23.27M |
-3106.9% |
| 2020 |
$-20.52 |
$14M |
$-3.48M |
-24.8% |
| 2021 |
$-12.34 |
$1M |
$-110.09M |
-11009% |
| 2022 |
$-2.53 |
$15.22M |
$-57.01M |
-374.7% |
| 2023 |
$-2.44 |
$24.35M |
$-65.77M |
-270% |
| 2024 |
$-2.36 |
$25.98M |
$-63.69M |
-245.1% |
| 2025 |
$-0.03 |
$7.15M |
$-20.6M |
-288.3% |
